<SEC-DOCUMENT>0001193125-13-180009.txt : 20130429
<SEC-HEADER>0001193125-13-180009.hdr.sgml : 20130427
<ACCEPTANCE-DATETIME>20130429090344
ACCESSION NUMBER:		0001193125-13-180009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130429
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130429
DATE AS OF CHANGE:		20130429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		13789268

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d527808d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>THE SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): April&nbsp;29, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALECTIN THERAPEUTICS INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-31791</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NORCROSS, GA 30071</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) (zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (678)&nbsp;620-3186 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION&nbsp;7 &#150; REGULATION FD </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;29, 2013, Galectin
Therapeutics&nbsp;Inc. (the &#147;Company&#148;) issued the attached press release, which is being furnished and not filed, and is attached hereto as Exhibit 99.1.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information in this report is being furnished pursuant to this Item&nbsp;7.01 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the
&#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date
hereof, except as expressly set forth by specific reference in such filing to this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND
EXHIBITS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Financial Statements of Businesses Acquired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pro Forma Financial Information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Shell Company Transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:51pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;Number</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated April 29, 2013</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin&nbsp;Therapeutics&nbsp;Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: April&nbsp;29, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter G. Traber, M.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter G. Traber, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer&nbsp;&amp; Chief Medical Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d527808dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g527808g85l31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151; Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>the International Liver Congress 2013 &#151; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Norcross, GA, April&nbsp;29, 2013</B> &#150; Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released data
that was presented on April&nbsp;27, 2013 at the International Liver Congress in Amsterdam, The Netherlands. The data were generated by the laboratory of Dr.&nbsp;Scott Friedman of the Icahn School of Medicine at Mount Sinai, a world renowned
investigator and expert on liver fibrosis. GR-MD-02 and GM-CT-01, drugs that inhibit galectin proteins, were found to reverse the most advanced stage of liver fibrosis, called cirrhosis, in experimental animals given toxin-induced cirrhosis.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The findings of these experiments show that the anti-galectin drugs had a robust effect on cirrhosis, including reversal of tissue
architectural changes in the liver that result from fibrosis as well as reduction in portal hypertension, an important pathophysiological effect of cirrhosis,&#148; said Dr.&nbsp;Friedman, Dean for Therapeutic Discovery and Chief, Division of Liver
Diseases at the Icahn School of Medicine at Mount Sinai. &#147;The experimental design of these studies provided a very high hurdle for any drug to show effectiveness, and yet both GR-MD-02 and GM-CT-01 passed the test. These drugs are excellent
candidates for evaluation in human cirrhosis.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are gratified that one of the most prominent investigators in the world has
shown that our galectin inhibitors were effective in experimental cirrhosis, the most severe form of liver fibrosis, for which there are no currently approved medical therapies&#148; said Dr.&nbsp;Peter&nbsp;G. Traber, President, Chief Executive
Officer and Chief Medical Officer, Galectin Therapeutics. &#147;Along with the multiple studies we have presented on liver fibrosis from fatty liver disease, these findings provide added confidence for the potential of this approach in studies of
human liver fibrosis and cirrhosis.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The data presented at the International Liver Congress which is sponsored by the European
Association for the Study of the Liver (EASL) are posted on the Company website at <U>http://bit.ly/14xDpKK</U>. Rats were treated with a liver toxin which produced fibrosis that replaced over 25% of the liver tissue and resulted in architectural
changes consistent with cirrhosis. While continuing to treat with the liver toxin, rats were treated with either a placebo or four weekly injections of either GR-MD-02 or GM-CT-01. The livers were reviewed by a highly qualified liver pathologist who
was unaware of the treatments that the animals had received. Both drugs significantly reduced the amount of fibrotic tissue, and most importantly, reversed the histological findings of cirrhosis. Additionally there was a reduction in the blood
pressure in the blood system supplying the liver (portal pressure) in the treated animals. Cirrhosis and portal hypertension are the primary abnormalities that lead to complications and death in humans with liver fibrosis. Galectin previously
announced initiation of a Phase 1 clinical trial of GR-MD-02 in patients with fatty liver disease (NASH, non-alcoholic steatohepatitis) with advanced fibrosis which is expected to begin enrolling patients in May 2013 (<U>http://bit.ly/11wj6hr</U>).
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g527808g85l31.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of
galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>This
press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use
words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from
those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as
to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property,
dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place
undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contact </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter G. Traber </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(678)&nbsp;620-3186 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ir@galectintherapeutics.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g527808g85l31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g527808g85l31.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)@">`P$1``(1`0,1`?_$`+T```$#!0$!`0``````
M``````@'"0H``P0%!@(!"P$``@(#`0$!`````````````0(``P0%!@<)"!``
M``<``0($`@4&!Q`#`````0(#!`4&!P@1"0`2$Q0A%2+24Y0*,9$CTQ8707&!
M)#1TM%&AP3)"8C-SLT2UEG<8.%AXV#H1``(`!`,$!P8$!`4%``````$"`!$#
M!"$2!3$3%`9!47&A(C(5\&&!L5('D<'1LJ(C,PAB4S14%N%"PR2T_]H`#`,!
M``(1`Q$`/P"2GSD[AM@ROD)A_;\X;4.I[+SSY"1*EG;,KY+S+/(..^4LF[EU
M,;+M:E>5"?>L4&;!PK'0;,Z#N2%+XJI%40!QD-=U!V3BNG;4P>G9!,5OBWRR
M;0*+VV=PG09?2#)E<NCP>`\>X7'4I$Q0,=FSSMW3)6['KQ%!$H)JVX7YT_B+
MHI_I`GJ+CPKL[(LX==LA"(8ARUWZ5Y^%X#[_`)#5ZQ9*EQHON]3&N4D\V;.=
MLAD=*SJE9O:,J;R\P[FZ>5-O,3;>TU^2]\M&2J#<&SYTT4375=KRJ!XF)^$3
M<TCY=OM[X=9^1Q?V*OWE;ZWA/4[A<$>2]D'ADBODD8'Q!%7^5RM_)_E>(=4N
M>E@WP@\-3ACW2>2O+O,>]GQ+X8S>C9M8>*O(_'M\UQI7(C*2UW08)SG,#/\`
MRRJS=Z=VNQ+3S:/?(LW17K1O%'==3IJH@4/I,+RI+>[&]NB$W-+$';#X7R.+
M^Q6^\K?6\#U2Z^ONAN&2*^1Q?V*WWE;ZWB>J77U]T3ADBOD<7]BM]Y6^MXGJ
MEU]?=$X9(KY%%_8K?>5OK>"NIW;&0?'LB<.D:Q@6IRCN981D@SD'U=D$HFP,
MV4L5TZ@Y5>-83*,;+H(K'5CGZT/*M794E0(<S9RDH`>10HB6U*\4R+]T3ATA
M'J]O7'BU[W?>,%>OT=*;QF%2@[S>\[0&:+*5^KV,S0(F37>+,TXAP"P2+8QT
MD7"BR)7*0J$*"A>N"G,8J7M33J=<&[I*"RY=@,;FORMJ]MH=OS+<6SIH=U5>
MG2JF65W3S`"<\/>(73Y'%_8K?>5OK>,SU2Z^ONC3<,D5\CB_L5OO*WUO$]4N
MOK[HG#)`.]P?=M%XL\?DM(Q+.XO3M*E=,SK/*Q29LM@?(3KV]3?R=-JR:5]_
M'R;B3.L8H(%*H!/,/4WT0$0TNO<Q:CIEAQ=HB5KEZJTP"LYYL,91ZK]FN0.6
MON#SB^@\U7E73]!I6%Q=5JU,J"JT$#3)>:RE,8">S`F.FQJT;=7L^9WOF]*\
M>\DDI1NBL2G4:0L:+:O++IE5"-F+I;;<Z9S4VW*/19"/9BB0W4"+*E`#CD6-
MWKK4P]\:*,R@A44B7:3M[(YSGFR^W-IJ+V'(!U&YTQ"1Q%V:2FH099J5*FBE
M$ZLY+-M(&R%)D;5^\&L/ICC7<,DO,O&D,*L=+S$C*QKE;H84VB\E6IM)W!.%
M_+T3,NV53$WY>@=1#:+=5Y>(^/KCB#1I%98SAK.Q]QG;JA8)JJV7'\YB;!79
M)U$3,8N[MIU64@R4%)P@8Z4^=)0"G#X&*82F*("`B`^&XJO_`)A_"*N&3WQW
MV2<Z=GUI]?(.OY1GK^S5[*[O>ZO"M75W`UDGJHU:O&5:-[1[*/@--E4.@EZ"
M"BON#I]"F#J`SBKC_,/X0R6U/,)XB%=KW(SE1-7V\YU(\1EZZ-/53;0^G/I2
M[CFM]7D-#H%1CW-?(,`6;.Q8UB;GYV0)YA502AVY2F.FY441=+FME8YIF0QE
MLQ$6O1IBHB`>$DSQ]QB/;V7KA)[O^(K[N.N7WU'EJK54T>EU8KP14/`UJM[/
M1<XC(Z/*MU.W;,:Q3&:!0(`%\IS=?B8>NON!E<H-DO\`I^<6)YHF5VJV5:B5
MR9N%VL<'4*E76*LI8+/9I5E!P$)&M^@KR$M+R2S=A',D0$/,JLH0A>OQ'QB#
MKC(@$G_+/MC2NQU;;G/,CB,IJM2HERR>!F$.2^5%<%J%ZGZC9+'7UXM*XB1\
MJM.4-@JEYTS*MS)*`3IZB@"[.6P,(J$;`?;XQ[UO5^9-RY9TKCIQ[SV.SO!U
M,5>:_I'->\5%31*FK//9SY'4<4R>J-+958^1NSU$AI62D)!RNW:1HD]-JH8Y
M3A:E-<H)VPC,V:71"!8]S;W6D]T*P=LGD-)9KJYK!QI)R<Q[<,ZJ[W.YYO&Q
MUD"M6?-=8S]6T7&(1FD#]7T=)Q[IH1=F)`4:`90#%%1`)2VX]T%"3,G9A`W<
ML?\`]'/:>_\`B'S*_P""R/AA_2^$*?.8)+E'W,8NH\W:OV^<MT#(,KOC3*UM
MNW_>MN6([IN.TAXZ:1U*I=3J!['44[SKU_<OB.D47,DU81,27W:I'9E"-_"4
MT4SGMAW+2!&R./PKN565GW#*WP*TB^Y7R8J&RY+(:;AO*'!:X[@XV'M%9-.J
M6S%]PA(ZQW6H1%D6B:^M)0LDPD&Q73<2(+,R*J$.-AIH>V$#,(42B\V=>YM<
MJ>37'CAO,4#.<CX:6*,S3<>2=[J+[396W;I(HO'3_*\<H#:STZ$2C*(WCSDG
M;!*/70"\.1NU8F+U<^(*:"(78PK.%7KN'3.A<L<'V:AYK`M\S9TUUQ=YELJJ
M^_=MM;2YQ;MU(-[=B#72/V@86K-G[?V\FDSG&3)Z)B&3%`#`!B$4',-L#,VR
M&P>P1H_,[=\JY7:Q>=@R.VN9?N,[_':@]M&5VT]NL;VG1.<U%0M-D('486KT
M>N)UV"9M(B//$R01B*'E.=SXC(K'&+%:8Q&/N^$+AQ9Y;<E)[O3\F>%^\9MQ
M2B!H/$BJZZWU7#J/:(Z_WYC-6JFLZI&7"Y7&8?33B-KC&9>H?+@3%N1<A54S
M^7Z/BIJ%!7-8(HK,`"P'B($Y`G:8LXR\J4%M'K56LT8LM,L2BLVUE78">DC;
M&IM'/SN%TON\E[>)Z#QJT.HZ%QCL.XY-.UEE>J<I3VPWA:`C;+M<W/VNPNG\
M;4X^">D=Q]?8`O,.W;,B!FA3K*-V2FI7Q>WYQ2S$'PS^/M*.WV'F-S/X1\Y^
M#&(<A;;A7('!>?%]M6/0TUG^2V?&-$Q;4X:*82D.<B;W3=+A;O1)=660;C[@
M6L@D!3G$_P!$`4;=H87.PA[24@8>:6BC2\:RDCP<NWG(<SQNFX&-F6J#IJVE
M&8*%$$7S9!ZJ5-0/I$]0>G0?CXH=5WBJ0"`P(GU]??&51N;BBCFB[(*E,HP4
MR#*2"5,MH)`F-AE$9#EYJ-EU7?=`=3[MR:.JUIFJ=5X=10XLX.'K\FXB2@V:
MB;TDWD@LV,X<J``'44/T$?*4H!E2Z\3&)F)$C[>[LAQR@]M:VTIPE:*-R8L-
M/EY2$59.7L)3DVK@\=+M`*[9**%L_10@E4ZD,(>=,X`H02G*!@,".?/VF2*G
M.HKO;U954YE%5EJ(DJJJHH83**JJJ6@QU%%#F$3&,(B81ZB/@3$2"`XT<#"<
M=-,+HY=/5MAB5V8@0B3U=*'`0ECLCBZ]V2:?CU0]G_B^G]+S?E#I\59@%S+(
MP5$S!].C#[B-^/\`O*_\7]!<A_A\-3J,:-1L)@#]P@U`-\G:?D8B/;%B]H[.
M_>FF>YPXK$]*]OSFQ7Y:E<E;Q4X20GR<9[]=E*Y)/+9?(B%;NY%EG#R_59I+
M#*@@9NV1D'J2@E410!<5U+5RHZ)@_*`C`KGZ(E.Q>O8Q;L[)IT1J&8V+*7T2
M$R6_,[G5I.@N8,Z/N/F9[*216@#1OM_IBH9;TP+\1Z>*1188S$79P1TQ#S[;
M=0SWD)^)1YI\J<NQ]W/\7WN:WM/+=F)E$DVQZQ7R,CL4I=CL=%N+J`1J,B]L
M4E'S:K9XT7,K(-E%ETQ,14YAN9@N)BM.F7N^<.E\D^=MET;N]P':VG];/Q)X
M\U'CX7>-%T-E9&N>:1R6FY`(U>(R+.--D56:F>4J-CW:R\N]@U$+"]-&O&S9
MZS*F8PD&8GT0K&9@)HW2^&>,?B&,<MV8S-$SC`ZWVS]N8R6C@@YAJ+=[77M%
M?35MFX?1YLH)[1*LXEGY'DRT?3"CAPW,@+A59(Y2F!"\\K=VQM3\1=VH9`VF
M4IHU0XE<HVL@:3LD/$*PKZYP$VM5XNP-I5XS<P,U-`R4*@R=D1=G4*)`3\_T
M?$B19ATE>'GXE/7=,VU1O7<7[CO%:ITS`=4GUFK6D2&LY<SSM.1RA6RO#EBX
MVWO6E+=N&+!59-1^FZ;>@50Z@`"JP8X;(L'A&.V<2'YK:,UK.GT/&E)A)]I6
MADFI*(J->:?.).,KM=BG$I*W.VIL`4+5*>@HDBQ3D7PHHN)-XV:HBHLJ!004
MSO,V$H8^)9XQ'/[(!S\.N;?=7X#[X^;TW8+URIL/*_$!LZI(LVZXWHR\DD%J
MH+Y\**5L&"(FP]^BU.JNS6=*$4(4R"WE-1"^`]ML*/!(G&<2.8W8:/,:W*8Q
M!/U9ZYUJI)W*X_)2(2$-2&3Z40BJ_$VV41<B2'LUK$73F-CS%%PNRCW*Y@(F
M5,5$2FRM,Q&<$2$1W/P[^H9MD'''G/0]/OE2H=SIW=(Y*0]DJMHG8^'L,7)7
M:?J$136:T*]62E#N+7*$,WCB$2,9XL42I`80$`9Z98X0%8+MC$Q+5LN>?BC^
M71FND4)Q\U[=>3U&+]&WU]0)2U-+C17SJLQAB2!B/[`U9N"*J,TA.X(F/F$G
M0!'P:GD]NHQ$V^W7&9<];RLGXI7*$#Z50B*M.V/9Z.Z(:WP!?;71?69^41J*
MYA?^5&S*QI1<%8&$'0H_3\GE$!$IBGMU"`WF]NLQE]\/5,XK7<`[#4//WREP
MSRO<\W]CLR$I:81@YK4,I#4R-92D\U=/4E8B*>.I,A".7())";X`8>O@(A7;
M[_R@LP;N_.'?.?O.[/.`6%5'DMH;8TUD3S8\GH5XG(0QY)>O4O3I<\&I?8E!
M@"XS:%;7<-WJJ"/G.X8D5!$#*"F`AJ9+YAUB"'`7*>J`]WSAVUY(.&O)SB-<
M:/I5(UUFTMX(P]DCCPTZI(HE.I9J?9DEE89XTF/+ZB[=55$R+D3]!ZB*9+8K
MC&P;@OIM8L+;2N25P94/-Z"8+1*Q3R_@X*]1@@^8@I/3"4D%>K]79>V!5XJJ
MY$3(D$@@0HF.`83!$%3E,Q!"H\RL>YM\#^9NQ<?9MW8,WJM:Y091`WI`3-6-
MQDLWHTDREK=4U4S)N1K;F975)'.A\AG2*!7).A%$_&HU5&33+EC_`+:I^TQV
M_P!N,E3[B:`K*&0ZS9`AA-2.)I3!!F#\1$<'L%V&Q2?/6.:REBL,HU_<;I*O
MM9.=EI%MZI%JH!%?;O7:Z(JD`X]#=/,'4>@_'QYAR169]8RYGR[E\"QEY5Z-
MD?3#^\K3=*M?LZU>RM;:C5.KVPS)2IHTOYV$T4&7;$V!U_2(W^LK_P!B<>/8
MJ7^GJ]B_N$?)JI_6I]I^1CV#=N\BB,W;=!VT=L!:NVCI%-PV=-G"'I+MW+=8
MITET%TCB4Y#`)3%$0$.G@W#%;BH1MF(6@`:8!@84."_"IK,+3[7B1QM;2SAT
M+]PZ;XMGB)5Y`R@K&D5FB=?*R5D#+#YQ7,F*HJ?2\WF^/BG>O*6$7A9"0)E!
M0M&S9@T;L&+9NR8LT4FS1DS02:M&K=`A4T6[9L@4B*""*90*4A2@4H!T`/"L
M[,)&(%48B$@U#CEQ[V^3K<UM&$X[K<S3E!5J<MI>:TZ\R5:.*OKB,&]LT/)N
M8PHK_I!*B8A14`#=/,`#X*U&42&R`4!,XR+[Q\P35'5)?:=B.1Z*]S5TB]SI
MW><YJ%K<T-VV]N+=>G+3D0^4K9T#,T1)[,40*9%,0^)"B!WKQ,BQJYOC#QIL
M<M*V"P\=<*GYZ<?+RTW-3.19_*3$S*.5!7<24I)/Z\X>2$@X6$3G66.=0Y_B
M(B/@;UNF1$!DD"5\T"-HCG1-@O[[B#JV3<5-,AE..L+N#NJWFB3=IH2\TGHS
MNCMZ>2-G)5^S03C&;43M9<K4%$7'02MRE#QKC<:DMZ;-!1F*`J?]TCXR)3GL
MRB<_=U1VOHW+OH*Z]5:]%N=0:V(FA8***U=Y+=X^;RS!Z9QT?&R7X]XKJVTX
M32\FR[#W$;KT3GU0<9WGC^O,]!(MB57V!HSMML;Q(PZEN81TS*BW9KOBB=DP
M,=%,.I@\-3U57NZEH[(CI6RKM\0R9I$G`-M/8-D:Z[Y<KIHUGK-EGJT:EH:M
M432:2KM1F%GGR8*9RP+928O['>NWAR&JJ$SM]>RK:ZU3+!2&,'(6W*'>@N(6
M8U*1=0="D:8X-59260:7F68*,V+^,,"#M<H)@H)CD`SKJ]ENFK;Y325@"9$X
MG8%R[9]'681>4.8JEPML;8K7:E4<!F1<*(!JSS$2*`@D;0)GHA5LPN?%?(&L
M-EV3UR"RQC-Q\G:H2H5K*Y^CM)Q=C3HZ\3@H,$ZK%_-[BSIKIN[>-#`K*D('
MIJ$]5,Z9+UU"W=\F:3%20,K!B`)X`C;+HC!_X_JVZJ5C37=TZ@1BM2FP#,YI
MK,AI`%P0&V;#.1G"/0LAVW9_0WO+%KGN)-M>-3Z3<@VRP8FC6]1L%.OSXE4H
MEFK]BL=-B[99FUCE5RQ#1TR%PL*ZI6@B45"$-2FLV52FU7,5"TP^(E@3E!QZ
M"<![\(R'Y4UZC<"R>W9KG>/3(5E?*]-<U0.5)"E5\1G+"9Z#+/9O^W)`IL[U
M'9A@D2K"UJ8UYE8XK`(9O*0L+2;RVI%BMK9Y'T,)%A)4V].$FST$Q*^8+""Q
MRE3_`$G@-JUDU(U,X-,"9*JQ,@0I.PC!C(]1A1RUK:UMQN&%45UI2+*)NU,U
M5&T>=`67H,B!U1@VIIP\4NMF1C<(PJ.O52Y$99F]PM5[XW(J-I.]Z6YJ=A;%
MKUJBJ6LH^N<PVM[4&,HX7!FG*+IG<J@F8IS!M4HBJUM2DCK66F2P,LS"<A+I
MV2B^CR[=U+>G>55+4:UE7N$"/3SA:.=2S!FP4%"6`\64'*"1'7WB0X(6V3M5
MWT/.,;NDBU=(0TY>[/AL;;/VCD6EN:Y:C#1ETD:7((721870Z4)[9FZ=*(N@
M]'R@4@B%M34[90V1F(03S2P..60,I3GA(8X1C4N7=7JO3HI1_G51,+F4,`4W
M@++.:C=^($@`C'"&@_Q0`UXW9<G!J3)I&U0=6XVC6HYA$C!,6$"-I:C$,VD&
M9JR-#MFS`4R$:B@B+<H`02$$OE#84FSTU<$D,)_C&GK4GH56HU!)U,B)SQ&!
MQ&!^$?GK\<.>/,_B"D\:<9.3NQ8O$2+D7LA6J?;G9*<^>F$1.\=4N4+)U-5X
MH(_36]GZI_X3#X>*HZ;D3W(^?'+2`/4>1G+?;=3IJRA%G%(E[8I$TEVJG_HS
MR%0K#>"KLH9,0ZE]TV6Z&#J'Q\2)$X3L`=`_#N;X'^=S>`/X@K+\/&LUD3TN
MYE_MJO[3';_;,$_<;0`-OK5E_P#33@4OP_O_`)^1_P#T)TO_`&]2\>2\B8ZP
M"-FX?]JQ]//[S\?LK,;/6+;_`,T3=G7](C?ZRO\`V)QX]HI?Z>KV+^X1\CZG
M]:GVGY&+C50_LVO5!4.B"70>J`@/T"_$/TP#X:X4&LY+*"2,,<.Z!1P02Q$7
M?4-]BM^=#]?XQ\B_6O\`%^D73;J/=%>H;[%;\Z'Z_P`3(OUK_%^D2;=1[HKU
M#?8K?G0_7^)D7ZU_B_2)-NH]T5ZAOL5OSH?K_$R+]:_Q?I$FW4>Z*]0WV*WY
M!_A1_N?Z_P`,B*&!S*?Q_2)-N@?*!42KN:AS3>VC]O[F?;3\<F+!;-QBV04I
M+&@T1^9I-I2@5DJ(S8W[UP,7YR9[Y.@&;@W\IO&N%&W]3+BL_%\./#)LNZS8
M2.24Y]1G+W1T?$ZG_P`/6VX>GZ/ZBQ%7-X^(W*S4KGGEW4C/)E_Q3F(2R;J&
M!CKTU*S&K7\EF'EG"3\Q6585L,`794^*ZS"/HZCL*08!J;CCYYWJJX/12!U\
M!?%=_P`W\8U>AIO&FI4K^+BP2I!R[S=2RSR_1,SG+WQM[>]U_P!.2G;6=#<>
MDE%?/XN'XP%JLC5EGXJ2A<L_\&7&-?"4WCP''#&&L/K6C&PQ2T\993$I)"%1
M*Y;HL]`@7F"UH2*4,TZLQE+"K%M'"TLW!Z$>FB+M=`GJ+GB6^G\+3R7'_J[R
MF4DN$\QR#!.D])ZAL$)=7FNG7+MKFTHC6-W>+<!G$IFDPNG$ZF4$)F,D,ISR
M@G"/-SJN&!R64LKK2M9/NZ=JLTI4L]DHY0D*XD&F!.F4W6ZY)3M$,*>8RE&!
M1V*K>7"'3G/>%0<$?BZ1*M>A8<?F2M5]3SL5$GV[HS433+ERS(,Y3V&<6Z?=
MZX>7C;I:VHT,I26K55AF`-U.F]15JSWP?PR*9S3EX<DF(X9?5N,XXIQ\2W;2
M+@GILSQMXE-J2O\`+W"HU&$9:S2_W5/Z&:'HJ,?)*RVYGAQ<?-47;P&96H2*
M*#3U#&UU.AI7!4?5:QX@T*<IAIJ-X)'!<27D,?E'1:A<\VC6-1]!MP=.2_O#
M6Q`-0FBV]%7-4S*%H9I99#-FREF@CN1U)P.6)),M5V+4ZS-L^.FPMK9,52#1
M<2,OA4A>Z&I>GYF\/GT_%-2P5Q)#D9EC4$W9V1U`!-PV]90FZO*%BPE5K,K;
MIL5!/AWBYO*A'GD#T]\<GH5[K%)\]A9VM6F;R@56HP$JPI5-V"6JJ2#3WA\1
MRY@)D-('?W2G8B]L&AN)36=&AWJW*;C*[N+%A"L5V33D/!LL<#+(UH=:BR'F
M87-LG4QDA065BT/.?S+,Q]T!%JV]J:]0M7(J&XID@*<'"C*/+TB6.P1+.\UQ
M+>@!:4'I#3+L4R6D3:L:^]8_S!XJ9-7+,!B`)*WAGK(^I<<%..-M.WU.P-^+
M,E9-)?.T;?#02F=5U(NMS#S2(>6/>J6(/J2IH"4@U1-,"NW*R4,+%<4@17+!
M0LN!8BNWIY<F4C(>/Q#R9O/.+'O.8!S)1S6E,\R+2H@;MSO'.X`I,-U4PJ;K
M(S9#/,/&H,U@9>Y[3^W79^V#5ZQSEU78,ZX7).<'-&Z-7XS07VENG+%1A^ZT
MDLPB\ZO5^(XFE`2][[J"(J01'UQ0'J(;:S6D+6F*)!HY!(^+$2VXB?XQR6L/
M=/JMR]ZM-+PUW-14RY`^8Y@N4LL@9^4D=1,10_\`MY_"`?\`O9S)_P"3N2'_
M`-.O&5(=8[_TC71]#CU^$!Z_^=G,C^6G<C^G]_AWX$AUCO\`TB1*?[9U+[:=
M:[6FF57A1KFI:#P?=#R(_;#2KM%71G>(T\C$.":Y[./M.;4>UJE@6`G.T].!
M7]0P?H?<?D\8.HI1:SJ+<OEM=VV<C,3ERF<I*3@,=D=)R=4UBES9I=7EZFE7
M7UU&W-LCE0KW`JJ:2L795`9Y`EF51/$@8PBO;&SSM(U?DRTE.%N\;+I&S%SB
MW-D:Y=H.^Q\*>GK*0OSZ0,XL^0T:,!XU.1MZ91?`H/G'RIG^/EXCENVY1IWJ
MG0KAWNMTV!%4`IUG-3`P[>R/U_\`W`:W_<W?\@\/]V-&TVQY3X^B35H5+1GW
MX#[M0*%Y7:3#-,Y,L]I!B0RY./N([]$J'1RN/Q]'X_S)P'0.BP_$/R_'IX]!
:I*NXJ#,)2&..'B'NGW1^':A.^3#I/R,?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
